Oyster Point Pharma, Inc.
Q4 2020 Earnings Call Transcript

Published: 18 Feb 2021

[Operator:]

Good evening and welcome to Oyster Point Pharma’s Fourth Quarter 2020 Earnings Conference Call. My name is Josh, and I’ll be your operator today. After the company’s formal remarks, there will be question-and-answer session. At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma’s, Chief Financial Officer. Sir, please go ahead.

[Daniel Lochner:]

Good evening, everyone, and welcome to the Oyster Point Pharma’s fourth quarter earnings conference call for the three months ending December 31, 2020. This evening, we issued a press release containing our fourth quarter financial results and recent business highlights.

[Jeffrey Nau:]

Thank you, Dan. Good evening everyone and thank you for joining us on our call today to discuss our fourth quarter 2020 financial results and recent business highlights. As you know on December 17, 2020 we submitted our NDA for OC-01 nasal spray with an indication for the treatment of the signs and symptoms of dry eye disease. In the coming days we expect to hear back from the FDA regarding the acceptance of our NDA for review and the PDUFA date if accepted.

[John Snisarenko:]

Thank you, Jeff. The dry eye disease segment is a large market with over 16 million people diagnosed in the United States alone. Only a small proportion of these patients approximately 2 million are currently being treated with a branded therapeutic and over 7 million people diagnosed with dry eye disease have tried and abandoned the currently available options.

[Daniel Lochner:]

Thank you, John. I will now provide a brief overview of Oyster Point Pharma’s fourth quarter financial results. Additional detail about the fourth quarter as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2020 Oyster Point Pharma reported net loss of $22.2 million or $0.86 per share compared to a net loss of $19.7 million or $1.41 per share for the same period in 2019.

[Operator:]

Our first question comes from Anupam Rama with JPMorgan. You may proceed with your questions.

[Anupam Rama:]

Just two quick ones for me it's still 60 days right from the December 17 filing for when you would hear PDUFA right and so we're sitting here on February 18 is there something like COVID related or anything in terms of timelines we should be thinking about here for the PDUFA? And then second question is you mentioned the medical meetings on for OC-01 where that the recent data will be highlighted, any new additional analysis we should be looking at for at these conferences? Thanks so much.

[Jeffrey Nau:]

Thanks Anupam for the question. I'll take the first question first, though just to remind everyone the timelines for review from the FDA. So as this is a 505(b)(2) product, we have a standard 10-month review cycle and the FDA is required to provide feedback to us in writing by day 74. So just as a reminder, we filed our NDA back in December 17, 2020. And so we're still within that day 74 window. We've had good conversations with the FDA. And as we stated in our prepared remarks, once we do receive that letter we will issue a press release.

[Operator:]

Our next question comes from Tara Bancroft with Piper Sandler. You may proceed with your question.

[Tara Bancroft:]

I guess using the TrueTear experiences as a lens of sorts. Do you anticipate any read through from that from payers on the intranasal delivery of your product? And I guess in the same vein have you had more detailed discussions on coverage yet and the positioning and the treatment paradigm? And if you can't provide details of that what is the general sentiment you're hearing on especially for coverage and first-line setting or do you think a step through will be required?

[John Snisarenko:]

Yes. Thanks Tara…

[Jeffrey Nau:]

Oh sorry. Go ahead John.

[John Snisarenko:]

Yes. Thanks Tara. I will address the question around the pairs from a TrueTear perspective, TrueTear was a medical device that was not reimbursed from a traditional pair perspective. Since this is ocular education, we do expect the standard commercial insurance as well as Medicare down the line to list on formulary OC-01. What we've had to date we've done quite a bit of extensive research and we've had some headboards with payers. So we have a good idea of what they're looking for namely differentiation of the product as well as competitive contracting. It's going to be key to get competitive listing on the commercial plans. And then we have to wait for the cycle of contracting for Medicare that we expect for the 2023 year. We are building a compelling dossier to be used as monotherapy first-line for dry eye disease for the signs and symptoms. And we're going in with that position with very competitive contracting strategy.

[Operator:]

Our next question comes from Ken Cacciatore with Cowen & Co. You may proceed with your question.

[Ken Cacciatore:]

Hi Jeff, Dan and John thanks for the call. I appreciate it. I was wondering maybe John you can talk a little bit about some of the lessons learned from this Xiidra launch I have some intimate understanding of what went right, what went wrong and a little bit of maybe a background around that the pricing issues that Xiidra and Restasis had I think that they kind of a got - they’re locked into a little bit of a pricing battle. So wondering where that is stricken out if you feel that the marketplaces kind of condition now for you all and more stable around that?

[John Snisarenko:]

Yes Ken I'll address these questions. Let's start with kind of the marketplace in general. One of the things that we did learn from the Xiidra launch was that the market is very promotionally sensitive both from a field force perspective as well as an investment interactor consumer. We've seen the market grow as high as double-digits 30% when good effort is put behind educating the consumer around dry disease and getting your eyes checked and getting treatment so that's a very positive lesson that we've taken away. We're going to be much more precise with our DTC efforts initially as we're getting payer coverage, we’re going to be really targeting a lot more digitally and not casting the net as wide, but as we do get more favorable coverage and then eventually Medicare, we plan on having quite an extensive direct-to-consumer campaign as we've seen this market react quite well to it. Especially with our therapeutic product profile, the only nasal spray on the market for dry eye disease is, it’s something that the patients could easily identify and ask for when they're coming into the eye care provider. You mentioned also pricing. I think all the branded products, now there are four of them approved on the market, they all range between $500 and $600 wax wholesale acquisition cost on a monthly basis. And you know I think that pricing has kind of settled that the branded products are at that price. I think it's going to be important how we approach the payers from a contracting strategy. But I think overall that market has stabilized and that pricing is kind of been that for quite a few years now. And last on the question around the market evolving, you know the space has been around 15 plus years as I have been now four regards of new competitors that have come on the market. We feel that this market still has a lot of headroom in regards to market potential. A lot of these products do focus in on kind of later stage disease, the inflammatory component. We feel that a product such as OC-01 as that is acting more upstream on restoring natural tear film and tear film homeostasis is conducive for the market to be used more upstream such as mild and moderate disease in addition to moderate to severe disease. So, we're quite excited that we'll be able to grow the segment, the prescription therapeutic segment and a lot of our commercialization efforts are going to be around that education as well as expansion of that market.

[Operator:]

Our next question comes from Patrick Dolezal with LifeSci Capital. You may proceed with your question.

[Patrick Dolezal:]

Hi, thanks for taking the questions and so few from me. Perhaps you could help us think about the unmet need and neurotrophic keratopathy and the rationale for OC-01 in this indication? And then more specifically on the Olympia study, just curious about any takeaways from the broader OC-01 experience in dry eye that might speak to the ability of OC-01 to improve corneal staining? And then maybe in a more general sense just you guys could contextualize how you're thinking about pursuing additional label expansion and whether there's anything else that might be expected in the relative near-term?

[Jeffrey Nau:]

Yes, great thanks, Patrick. Those are great questions. So as we think about neurotrophic keratopathy one of the things I think is important is to understand the disease state. When we think about patients with this disease, think about it almost as a, patients who is diabetic that has peripheral neuropathy only it's in their cornea. So that underlying nerve plexus in the cornea is not providing feedback back to the brain to say blink or tear. And so we get a breakdown not only from the lack of blinking and tear production, but also because those underlying nerves keep that corneal epithelium healthy. The way in which OC-01 nasal spray works is by completely bypassing the ocular surface. Therefore we think this is actually a really important product for these patients because we can stimulate natural tear film production. We can do it many times a day. We are contemplating actually treating more than twice a day that we did in the dry eye program in the NK program. And we think that these patients will benefit because we don’t rely on that underlying nerve plexus. And as we have stated previously, the lacrimal gland produces a whole myriad of growth factors including nerve growth factor, epidermal growth factor and we think that those are going to be important for healing that corneal surface. When we look at the different stages of neurotrophic keratopathy, we’re really focused with OC-01 as a standalone agent right now for Stage 1 and Stage 2, NK in our clinical trials as we develop the pipeline internally. There may be other things that we look out for those Stage 3 patients. But we think that actually all three patients, all three stages of patients could benefit from a treatment such as OC-01 Because regardless of whether you have corneal hyperplasia or you have a corneal ulcer that stimulation of the natural tear film could be beneficial to those patients. And as we know today one of the only therapies that’s out there for those Stage 3 patients its taking quite a long time for that therapy to get to the patient and work its way through the payer system. And so, we think that this could potentially be a product that we may ultimately look at to sort of bridge those patients during that time. So more to come, but right now we are really focused on Stage 1 and Stage 2 patients and we think that this product just has a very unique mechanism of action to be able to improve the health of the corneal surface. When we look at the corneal staining data that we did see in the ONSET-1 and ONSET-2 studies a couple of different points one, is we’re really encouraged by the data as you saw in the ONSET-1 study. We had statistically significant improvement in multiple areas of the cornea. And again, we’re one of the few companies that have shown our data across all areas of the NEI scale not just one specific area. And then in the OCO - sorry the ONSET-2 program again we saw a directional benefit in all of the areas of the cornea with regards to staining. And we will be presenting some additional data as we go forward on certain subsets of that patient population. But two things to keep in mind on the dry eye side one is, we only treated for 28 days. So sometimes staining resolution take some period of time. And second, because we were focused on looking at the patient Schirmer scores we had to give topical proparacaine pretty often over the course of the study which we know can also exacerbate staining. So when we look at neurotrophic keratitis we obviously won’t have as much proparacaine on ocular surface. We’ll be treating over a 56-day period so much longer period of time and we’re really excited to see the data in that patient population.

[Operator:]

Thank you. I will now turn the call back over to Dr. Nau for any closing remarks.

[Jeffrey Nau:]

Thank you, Operator. I’m extremely proud of the progress that the Oyster Point team has made in developing OC-01 nasal spray specifically through the efficient development program that began in May of 2018 when we filed the initial IND application for this product. I look forward to the team’s continued execution through developing and advancing additional pipeline assets in line with our goal to expand the pipeline to other ophthalmic indications initially focused on transformative therapies for diseases of the ocular surface. In addition, we have continued to bolster our R&D and clinical development capabilities as well as strengthen our manufacturing team. In 2021, we will also continue to enhance our commercial capabilities including a plan competitively sized ophthalmic sales force to launch OC-01 nasal spray in the fourth quarter of 2021 if approved. We are driven to build Oyster Point into a world-class ophthalmology company. In closing, I’d like to thank everyone for joining us today and I hope that your family stays safe and healthy.

[Operator:]

Thank you. Ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.